OSE Immunotherapeutics Stock price




Biotechnology & Medical Research

Market Closed - Euronext Paris 11:35:26 2023-12-07 am EST Intraday chart for OSE Immunotherapeutics Pre-market 02:01:24 am
4.025 EUR -3.48% 4.033 +0.20%
Sales 2023 * 3M 3.24M Sales 2024 * 23.87M 25.74M Capitalization 75.75M 81.69M
Net income 2023 * -22M -23.73M Net income 2024 * -10M -10.78M EV / Sales 2023 *
Net Debt 2023 * 33.7M 36.35M Net Debt 2024 * 45.46M 49.03M EV / Sales 2024 *
P/E ratio 2023 *
P/E ratio 2024 *
Employees 62
Yield 2023 *
Yield 2024 *
Free-Float 80.64%
More Fundamentals * Assessed data
Dynamic Chart
Ose Immunotherapeutics, GenDx to Co-develop Diagnostic Test Companion for Cancer Vaccine Trial MT
OSE Immuno: collaboration agreement with GenDx CF
OSE Immunotherapeutics SA Announces A Collaboration Agreement with Genome Diagnostics B.V. for the Development of A Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®? CI
Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody CI
OSE Immunotherapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
OSE Immunotherapeutics' Lung Cancer Vaccine Extends Survival in Late-stage Study MT
OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation CI
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation CI
OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist CI
OSE Immunotherapeutics Wins Cancer Vaccine Patent in US MT
OSE Immunotherapeutics SA Announces New US Patent Granted for the Use of Tedopi in Cancer Patients After Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment CI
OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director CI
Global markets live: Boeing, Tesla, Fedex, Roche, Buzzi...
OSE Immunotherapeutics SA Receives EUR 1.5 Million in Funding from Bpifrance for the Development of A Companion Diagnostic for the Cancer Vaccine Tedopi®? in Non-Small Cell Lung Cancer CI
OSE Immunotherapeutics SA announced that it has received €1.5 million in funding from Bpifrance Investissement SAS CI
More news
1 day-3.48%
1 week+2.55%
Current month+2.55%
1 month-10.16%
3 months+24.81%
6 months+9.67%
Current year-39.70%
More quotes
1 week
Extreme 3.89
1 month
Extreme 3.81
Current year
Extreme 2.705
1 year
Extreme 2.705
3 years
Extreme 2.705
5 years
Extreme 2.7
10 years
Extreme 2.7
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 2016
Founder 68 2004
Director of Finance/CFO - 2016
Members of the board TitleAgeSince
Founder 68 2004
Director/Board Member 66 2022
Director/Board Member 67 2016
More insiders
Date Price Change Volume
23-12-07 4.025 -3.48% 37,582
23-12-06 4.17 +2.71% 60,604
23-12-05 4.06 +3.31% 68,318
23-12-04 3.93 +0.51% 64,324
23-12-01 3.91 -0.38% 45,096

Real-time Euronext Paris, December 07, 2023 at 11:35 am EST

More quotes
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). Its well-balanced first-in-class clinical pipeline is as follows: - Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company's most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or lymphomas (first patient included). OSE-279 is the backbone therapy of the BiCKI® platfor; - OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics); - FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.); - OSE-172/BI 765063 (anti-SIRP? monoclonal antibody on CD47/SIRP? pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC). OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies: - BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI® candidate targeting anti-PD1xIL-7; - Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock OSE Immunotherapeutics - Euronext Paris
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration